Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• High-grade extremity soft tissue sarcomas are aggressive tumors.
• Treatment outcomes for these sarcomas can vary significantly.
• Understanding the role of neoadjuvant chemotherapy is crucial for improving patient survival.

Purpose of the Study:

• To retrospectively analyze the impact of neoadjuvant chemotherapy (NAC) on outcomes in patients with high-grade extremity sarcomas.
• To determine if NAC influences disease-specific survival and recurrence rates.
• To identify specific tumor characteristics that may benefit from NAC.

Main Methods:

• Retrospective analysis of patients diagnosed between 1990 and 2001 with high-grade, deep, extremity soft tissue sarcomas (>5 cm).
• Comparison of outcomes between patients treated with surgery alone (n=282) and those receiving NAC with doxorubicin/ifosfamide/mesna (AIM) (n=74).
• Utilized a stratified Cox proportional hazards model to assess the effect of NAC on disease-specific survival and recurrence, adjusting for prognostic factors.

Main Results:

• Neoadjuvant chemotherapy (NAC) was associated with improved disease-specific survival (P=0.02).
• The survival benefit of NAC was particularly evident in patients with tumors larger than 10 cm.
• For tumors >10 cm, 3-year disease-specific survival increased from 0.62 (no NAC) to 0.83 (with NAC).

Conclusions:

• Neoadjuvant chemotherapy (NAC) using doxorubicin/ifosfamide/mesna (AIM) significantly improved disease-specific survival in patients with high-grade extremity soft tissue sarcomas >10 cm.
• These findings highlight the potential benefit of NAC for large, high-grade extremity sarcomas.
• Further prospective studies are recommended to confirm these results and explore neoadjuvant or adjuvant chemotherapy strategies for this patient group.